Please take a moment to review the important CME information on this page.

To earn free CME credit for watching this program, you must complete the online CME test and evaluation. You must be registered and signed-in in order to take the test online. Upon successful completion of the test and the evaluation, you will be asked to select your professional category and will be able to print the appropriate credit certificate right from your computer. You must answer a minimum of 7 out of 10 questions correct in order to earn CME credit.

Take the online CME test and evaluation.

Click here for a list of CME Requirements by State.

Type 2 Diabetes: New Treatment Strategies

Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin Medical School and Discovery Health Channel in partnership with ProCom International. The University of Wisconsin Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Wisconsin Medical School designates this educational activity for a maximum of 1 AMA PRA Category 1 Creditâ„¢. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Program Overview
Diabetes is the sixth leading cause of death in the United States today. Traditional strategies for the management of type 2 diabetes do not address the underlying mechanisms responsible for maintaining optimal glycemic control and, consequently, lead to disease progression and the development of cardiovascular disease and other complications. Several recent studies have shown that intervention at the stage of impaired glucose tolerance, which is early relative to the contemporary clinical practice of treating established diabetes, can delay the onset of type 2 diabetes. This program will help physicians reevaluate current treatment strategies to recognize the importance of identifying and treating high-risk individuals before the disease progresses.

This program is funded through an educational grant from GlaxoSmithKline.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Recognize the importance of implementing more aggressive screening and lifestyle modification approaches for type 2 diabetes in clinical practice.
• Explain that effective treatment plans for type 2 diabetes must go beyond glycemic control to address the coexisting manifestations of insulin resistance and β-cell dysfunction.
• Demonstrate that early treatment with pharmacologic agents such as thiazolidinediones (TZDs) modify insulin resistance and may alter the natural history of type 2 diabetes.
• Describe the mechanism of action of TZDs and demonstrate how, when used in combination with other antidiabetic medications, these agents can manage the coexisting cardiovascular complications of the disease.
• Discuss the consensus recommendations from the American Diabetes Association and the American Heart Association for effective utilization of TZDs in clinical practice.
• Utilize observational and laboratory findings to diagnose metabolic syndrome.

Target Audience
This program has been developed for physicians who diagnose, manage, and treat patients with type 2 diabetes.

This program is intended solely for the education of physicians and other healthcare professionals. Any consumers who view this program should consult their physicians regarding how to best manage type 2 diabetes.

Term of Approval
The CME test is valid through June 6, 2006. No credit will be issued after this date.

Faculty Disclosure Information

James R. Gavin III, M.D., Ph.D.
Consultant for: Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind, Novartis, Pfizer, sanofi-aventis

James R. LaSalle, D.O., F.A.A.F.P.
Consultant for: GlaxoSmithKline, Pfizer, Takeda Pharmaceutical Company Limited
Stock Shareholder for: Pfizer
Honorarium: GlaxoSmithKline, Pfizer, Takeda Pharmaceutical Company Limited
Richard W. Nesto, M.D.
Honorarium: GlaxoSmithKline, Takeda Pharmaceutical Company Limited